

## 2022 Update on Heart Transplant

1. Advances pre-transplant
  - a. Expansion of the donor pool
    - i. Hepatitis C donors
    - ii. Donation after circulatory death donors
    - iii. COVID-19 positive donors
    - iv. Novel organ preservation techniques
  - b. Expanding the recipient pool
    - i. Infiltrative heart disease
    - ii. Allosensitization
    - iii. Older recipients
    - iv. Congenital heart disease
  - c. Supporting the failing heart
    - i. Short-term MCS
    - ii. Long-term MCS support
2. Advances after transplant
  - a. New immunosuppressive agents
    - i. Daratumumab
    - ii. Belatacept
    - iii. Tocilizumab
    - iv. IgG endopeptidase
  - b. Novel monitoring strategies
    - i. Gene expression profiling
    - ii. Donor-derived cell-free DNA
    - iii. MicroRNA
    - iv. Anelloviruses
3. Challenges on the horizon
  - a. Multiorgan transplant
  - b. Re-do transplant
  - c. Xenotransplantation